Head and Neck Cancer Clinical Trial
Official title:
A Phase II Study of Cetuximab, Carboplatin and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Verified date | July 2017 |
Source | Trans-Tasman Radiation Oncology Group (TROG) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase II study of cetuximab, carboplatin and radiotherapy (RT) in patients with
Locally Advanced Head and Neck Carcinomas (LAHNC) who are unfit for cisplatin.
The aim of this study is to show the feasibility and safety profile of the combination of
cetuximab, carboplatin and RT in treatment of patients with LAHNC.
Status | Completed |
Enrollment | 60 |
Est. completion date | December 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Previously untreated SCC of the oropharynx, larynx or hypopharynx. - Stage III or IV, excluding T1N1, and metastatic disease (to be confirmed by a chest CT, and abdominal CT or ultrasound scan if patients with abnormal liver function tests or a bone scan or FDG-PET if patients with bone pain). - Histologically or cytologically confirmed HNSCC - Disease must be considered potentially curable by chemoradiation - Patients medically unfit for cisplatin chemotherapy due to one or more of the following reasons: - Clinically significant sensori-neural hearing impairment (audiometric abnormalities without corresponding clinical deafness will not be regarded as a contraindication to cisplatin) - Severe tinnitus - Renal impairment (GFR < 60ml/min) - Peripheral neuropathy > grade 2 - Inability to tolerate intravenous hydration eg due to cardiac disease - Co-morbidities (based on clinical judgement by the investigator) associated with ECOG PS 2 that in the view of the investigator would preclude the safe administration of cisplatin - Performance status ECOG 0, 1 or 2. - Adequate haematological, renal and hepatic functions as defined by: - Absolute neutrophil count (ANC, segmented cells (segs) + bands)>= 1.5 x 109/L - Platelet count >= 100 x 109/L - Total bilirubin <= 1.5 x upper normal limit - Alanine aminotransferase <= 2.5 x upper normal limit - Calculated creatinine clearance > 40ml/min (Cockcroft-Gault formula). - If calculated creatinine clearance < 50 ml/min, glomerular filtration rate to be measured with DTPA or EDTA scan. If < 40 ml/min not eligible. - Age >18 years - Signed written consent - Suitable for follow-up for 4 years in the view of the investigator Exclusion Criteria: - Distant metastases, i.e., any metastatic disease below the clavicles. Patients with lung nodules >10mm will be excluded unless non-malignancy aetiology is established. Patients with lesions 5-10mm can be included if a FDG-PET scan is negative and the investigator considers on clinical grounds that metastasis is unlikely. Patients with lesions < 5mm can be included if the investigator considers on clinical grounds that metastases are unlikely. Patients with multiple lung nodules should not be included unless there is a strong case that these do not represent metastases, e.g., stable on imaging for over 12 months, non-malignant aetiology apparent. The level of clinical suspicion may be influenced by clinical stage, e.g., N3 disease, low neck nodes. In general if there is any doubt patients should be excluded. - Previous radical RT to the head & neck region, excluding superficial RT for a non-melanomatous skin cancer. - Patients with prior cancers, except: those diagnosed > 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix. - Significant intercurrent illness that will interfere with the chemotherapy or radiation therapy such as HIV infection, cardiac failure, pulmonary compromise, active infection - Any history of myocardial infarction, ventricular arrhythmias, or unstable angina within the last 6 months - Pregnant or lactating women. - Weight loss greater than 20 % of usual body weight in the 3 months preceding trial entry - High risk for poor compliance with therapy or follow up as assessed by the investigator - Prior radiation to greater than 30% of the bone marrow - Prior systemic chemotherapy for cancer - Refusal by male or female patients, to use appropriate contraception during the study and for 3 months afterwards - Any condition or circumstance which might prevent the patient being able to give valid informed consent, or from completing participation in the study |
Country | Name | City | State |
---|---|---|---|
Australia | Peter MacCallum Cancer Centre | Melbourne | Victoria |
Lead Sponsor | Collaborator |
---|---|
Trans-Tasman Radiation Oncology Group (TROG) |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and Feasibility | An initial 6 patients will be treated. Once all these patients have a 2 week post RT review there will be analysis. If <= 1 patient has a DLT than the treatment is deemed safe. | ||
Secondary | Failure free survival (FFS) | All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment. | ||
Secondary | Time to local and/or regional failure | All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment. | ||
Secondary | Overall survival | All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment. | ||
Secondary | Site of first failure | All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment. | ||
Secondary | Acute and late treatment toxicities | All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |